BioNano Genomics Inc vs Invesco DB Oil Fund — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Invesco DB Oil Fund trades at $20.98. The key difference: Invesco DB Oil Fund is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | DBO | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | Commodities - Energy |
52-Week High | $4.92 | $23.80 |
52-Week Low | $1.06 | $11.98 |
Enterprise Value | $16.26M | — |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
DBO trades at $20.99, up 0.67% today, with a bullish technical signal from moving averages. The stock shows neutral oscillators but faces uniform support and resistance at $21. Recent news highlights oil market volatility due to Middle East tensions and OPEC demand forecast cuts, influencing energy sector sentiment.
The outlook is clouded by supply disruptions and demand uncertainty, posing risks for energy stocks. Investment appeal hinges on oil price stability and company-specific fundamentals, which require verification from recent SEC filings and earnings reports for a complete assessment.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →